First off, I'd like to thank everyone who took the time to participate in our #ACTsocial Tweet Chat, and our discussion about the use of social media for clinical trials professionals. We really enjoyed the conversation and we're looking forward to potentially setting up Round 2 in the near future. Below I've compiled and organized a round-up of the tweets from the chat, but you can view the full stream on Twitter by searching the hashtag #ACTsocial. Make sure to keep hitting "Next Page" at the end of the Storify story until you reach the end. If you're having trouble viewing the embedded tweets, you can also view the wrap up here.
Social Media for Clinical Trials Professionals Tweet Chat
Applied Clinical Trials
First off, I'd like to thank everyone who took the time to participate in our #ACTsocial Tweet Chat, and our discussion about the use of social media for clinical trials professionals. We really enjoyed the conversation and we're looking forward to potentially setting up Round 2 in the near future. Below I've compiled and organized a round-up of the tweets from the chat, but you can view the full stream on Twitter by searching the hashtag #ACTsocial. Make sure to keep hitting "Next Page" at the end of the Storify story until you reach the end. If you're having trouble viewing the embedded tweets, you can also view the wrap up here.
[
View the story "#ACTsocial Wrap-up" on Storify
]
Tips to Rescue a Clinical Trial Before It’s Too Late
Why constant communication and transparency are paramount to successful partnerships between pharmaceutical companies and CROs
The Future of Personalized Medicine Hinges on Revolutionizing Business Models
The era of big pharma as product-first companies must end, as services become the larger priority.
Is Trust the Secret Ingredient for Digital Product Success?
To rebuild trust, companies should focus on transparent, neutral content incorporating medical expertise and regularly seeking HCP feedback.
FDA Inspections Face Continued Overhaul and Changes
Agency will be reorganizing field force and compliance functions.
Reaching for the ‘White Spots’ in Rare Disease
EU proposal focuses on a subset of underserved rare diseases—exploring the gaps in those conditions for which there is no approved treatment option.
The EU Regulations Catching US Pharma Companies Off Guard
Companies that understand the regulatory environment in Europe can keep their trials on budget and on schedule.
Tips to Rescue a Clinical Trial Before It’s Too Late
Why constant communication and transparency are paramount to successful partnerships between pharmaceutical companies and CROs
The Future of Personalized Medicine Hinges on Revolutionizing Business Models
The era of big pharma as product-first companies must end, as services become the larger priority.
Is Trust the Secret Ingredient for Digital Product Success?
To rebuild trust, companies should focus on transparent, neutral content incorporating medical expertise and regularly seeking HCP feedback.
FDA Inspections Face Continued Overhaul and Changes
Agency will be reorganizing field force and compliance functions.
Reaching for the ‘White Spots’ in Rare Disease
EU proposal focuses on a subset of underserved rare diseases—exploring the gaps in those conditions for which there is no approved treatment option.
The EU Regulations Catching US Pharma Companies Off Guard
Companies that understand the regulatory environment in Europe can keep their trials on budget and on schedule.